Jul 21
2026
Phanes Therapeutics announces expansion of clinical trial collaboration and supply agreement with Merck to evaluate spevatamig in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for treatment of biliary tract cancer
Spevatamig is Phanes' anti-CLDN18.2/CD47 bispecific antibody that functions as an innate immunity enhancer (I₂E), an emerging class of immuno-oncology (IO)...
Read More
Jun 22
2026
Phanes Therapeutics announces completion of enrollment in Phase 2 clinical trial of spevatamig in combination with chemotherapy for the frontline treatment of metastatic pancreatic ductal adenocarcinoma
Two dose levels of spevatamig in combination with standard of care chemotherapy are being evaluated as frontline (1L) treatment for metastatic...
Read More
May 28
2026
Phanes Therapeutics announces updated Phase 2 clinical trial results of spevatamig (PT886) in combination with chemotherapy in frontline treatment of metastatic PDAC at the 2026 ASCO annual meeting
SAN DIEGO, May 28, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Apr 22
2026
Phanes Therapeutics to present updated Phase 2 clinical trial results of spevatamig (PT886) in combination with chemotherapy in frontline treatment of metastatic PDAC at the 2026 ASCO annual meeting
SAN DIEGO, April 22, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Apr 7
2026
Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Mar 18
2026
Phanes Therapeutics to present three clinical posters at AACR 2026
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Jan 10
2026
Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
SAN DIEGO, Jan. 9, 2026 /PRNewswire/ -- Data presented at ASCO GI 2026 show spevatamig, an anti-CLDN18.2/CD47 bsAb, in combination with chemotherapy,...
Read More
Dec 10
2025
Phanes Therapeutics to present Phase 1/2 study results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic PDAC at ASCO GI 2026
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Sep 9
2025
Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy
SAN DIEGO, Sept. 8, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
May 27
2025
Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy
SAN DIEGO, May 27, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
